X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-08-14 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $2.09 | +11,608 | 2,760,000 | 0% | +$24,206 | ||||||
| D | 2026-08-17 | MANE | Veradermics, Inc | Durso Timothy August | Chief Technical Officer | S - Sale+OE | $107.82 | -43,500 | 78,142 | -36% | -$4,690,005 | |||||
| D | 2026-08-17 | MANE | Veradermics, Inc | Waldman Reid Alexander | CEO | S - Sale+OE | $107.86 | -67,500 | 170,824 | -28% | -$7,280,713 | |||||
2026-08-14 | ASND | Ascendis Pharma A/S | Bienaime Jean Jacques | Dir | P - Purchase | $246.33 | +2,000 | 2,900 | +222% | +$492,654 | ||||||
| DM | 2026-08-14 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO | S - Sale+OE | $36.34 | -664,826 | 18,630,739 | -3% | -$24,160,402 | |||||
| D | 2026-08-18 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale+OE | $32.03 | -4,767 | 25,655 | -16% | -$152,690 | |||||
| D | 2026-08-18 | STOK | Stoke Therapeutics, Inc. | Kaye Edward M. Md | Dir | S - Sale+OE | $32.03 | -12,567 | 124,557 | -9% | -$402,528 | |||||
| D | 2026-08-18 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | GC, Corp Sec | S - Sale+OE | $32.03 | -2,861 | 21,225 | -12% | -$91,639 | |||||
| D | 2026-08-17 | IRON | Disc Medicine, Inc. | Quisel John D | CEO | S - Sale+OE | $79.15 | -33,000 | 226,064 | -13% | -$2,611,982 | |||||
| D | 2026-08-14 | MLPT | Maplight Therapeutics, Inc. | Catalyst4, Inc. | 10% | P - Purchase | $11.38 | +4,400,000 | 25,306,689 | +21% | +$50,072,000 | |||||
| D | 2026-08-17 | JNJ | Johnson & Johnson | Taubert Jennifer L | EVP, WWC. Innovative Medicine | S - Sale+OE | $263.36 | -15,000 | 194,451 | -7% | -$3,950,400 | |||||
2026-08-14 | ADAG | Adagene Inc. | Do Cuong V | Dir | P - Purchase | $3.75 | +2,000 | 2,000 | New | +$7,500 | ||||||
2026-08-17 | ALXO | Alx Oncology Holdings Inc | Lettmann Jason | CEO | S - Sale | $1.93 | -2,230 | 294,379 | -1% | -$4,304 | ||||||
2026-08-17 | ALXO | Alx Oncology Holdings Inc | Wong Shelly | SVP, FINANCE, CAO | S - Sale | $1.93 | -573 | 87,828 | -1% | -$1,106 | ||||||
| D | 2026-08-17 | MCRB | Seres Therapeutics, Inc. | Brady Kelly | See Remarks | S - Sale+OE | $4.55 | -64 | 8,679 | -1% | -$291 | |||||
| D | 2026-08-17 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | Dir | S - Sale+OE | $4.55 | -263 | 12,499 | -2% | -$1,197 | |||||
| D | 2026-08-17 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R | See Remarks | S - Sale+OE | $4.55 | -81 | 7,995 | -1% | -$369 | |||||
| D | 2026-08-17 | MCRB | Seres Therapeutics, Inc. | Desrosier Thomas | See Remarks | S - Sale+OE | $4.55 | -82 | 8,117 | -1% | -$373 | |||||
2026-08-17 | PCRX | Pacira Biosciences, Inc. | Slonin Jonathan | Chief Medical Officer | S - Sale | $23.23 | -3,040 | 216,384 | -1% | -$70,619 | ||||||
| D | 2026-08-14 | ABBV | Abbvie Inc. | Donoghoe Nicholas | EVP, CHIEF BUS, STRAT OFFICER | S - Sale+OE | $250.00 | -32,710 | 74,430 | -31% | -$8,177,500 | |||||
2026-08-17 | VRCA | Verrica Pharmaceuticals Inc. | Zawitz David | COO | P - Purchase | $4.98 | +6,000 | 27,000 | +29% | +$29,880 | ||||||
| M | 2026-08-17 | VRCA | Verrica Pharmaceuticals Inc. | Rosenberg Noah L. | CMO | P - Purchase | $4.91 | +6,230 | 8,587 | +264% | +$30,610 | |||||
| M | 2026-08-14 | VRCA | Verrica Pharmaceuticals Inc. | Rieger Jayson | CEO, Pres | P - Purchase | $5.03 | +25,000 | 208,298 | +14% | +$125,750 | |||||
2026-08-18 | VRCA | Verrica Pharmaceuticals Inc. | Kirby John J. | Interim CFO | P - Purchase | $4.93 | +5,000 | 23,962 | +26% | +$24,650 | ||||||
| D | 2026-08-18 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $75.82 | -3,500 | 153,902 | -2% | -$265,370 | |||||
2026-08-18 | ELAN | Elanco Animal Health Inc | O'Neill Shiv | GC, CORP SEC | P - Purchase | $23.58 | +3,998 | 87,832 | +5% | +$94,273 | ||||||
| D | 2026-08-17 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $506.59 | -9,500 | 668,728 | -1% | -$4,812,568 | |||||
| D | 2026-08-14 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $114.49 | -3,664 | 119,472 | -3% | -$419,491 | |||||
2026-08-14 | CORT | Corcept Therapeutics Inc | Wilson James N | Dir | S - Sale | $111.43 | -10,000 | 1,474,543 | -1% | -$1,114,261 | ||||||
2026-08-17 | CORT | Corcept Therapeutics Inc | Robb Gary Charles | Chief Business Officer | S - Sale | $116.26 | -10,000 | 84,284 | -11% | -$1,162,572 | ||||||
| E | 2026-08-17 | LLY | Eli Lilly & Co | Jonsson Patrik | EVP, Pres, LLY Int'l | S - Sale | $0.18 | -6,500 | 54,779 | -11% | -$1,175 | |||||
| M | 2026-08-14 | NTHI | Neonc Technologies Holdings, Inc. | Chen Thomas C | CEO, 10% | P - Purchase | $3.86 | +36,259 | 4,660,135 | +1% | +$140,000 | |||||
2026-08-17 | AQST | Aquestive Therapeutics, Inc. | Barber Daniel | Pres, CEO | S - Sale | $4.29 | -25,000 | 585,574 | -4% | -$107,168 | ||||||
2026-08-18 | ABCL | Abcellera Biologics Inc. | Montalbano John S. | Dir | P - Purchase | $11.03 | +10,000 | 256,000 | +4% | +$110,300 | ||||||
2026-08-18 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | CEO, Pres, 10% | P - Purchase | $5.54 | +9,000 | 7,616,140 | 0% | +$49,860 | ||||||
2026-08-14 | PHVS | Pharvaris N.V. | Modig Berndt | CEO | S - Sale | $34.77 | -2,292 | 1,080,625 | 0% | -$79,686 | ||||||
2026-05-18 | CNSP | Cns Pharmaceuticals, Inc. | Fisher Michal | Dir | P - Purchase | $5.00 | +2,000 | 2,000 | New | +$10,000 | ||||||
| DM | 2026-04-23 | ENSC | Ensysce Biosciences, Inc. | Gower Bob G | Dir | P - Purchase | $0.49 | +908,614 | 916,740 | >999% | +$444,169 | |||||
| D | 2026-08-13 | OMER | Omeros Corp | Borges David J. | VP, Finance, CAO | S - Sale+OE | $16.95 | -5,000 | 0 | -100% | -$84,750 | |||||
2026-08-14 | APLM | Apollomics Inc. | Chen Yi-Kuei | COO | P - Purchase | $15.00 | +20,000 | 136,248 | +17% | +$300,000 | ||||||
2026-08-14 | APLM | Apollomics Inc. | Lin Peter Kuan-How | CFO | P - Purchase | $15.00 | +26,667 | 48,979 | +120% | +$400,005 | ||||||
2026-08-14 | APLM | Apollomics Inc. | Chen Hung-Wen | CEO | P - Purchase | $14.07 | +536,667 | 1,448,029 | +59% | +$7,550,004 | ||||||
2026-08-17 | ALKS | Alkermes Plc. | Nichols Christian Todd | SVP, Chief Commercial Officer | S - Sale | $49.23 | -7,576 | 102,193 | -7% | -$372,937 | ||||||
| M | 2026-08-14 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | CEO, Pres, 10% | P - Purchase | $3.91 | +15,000 | 7,607,140 | 0% | +$58,580 | |||||
| D | 2026-08-13 | CUE | Cue Biopharma, Inc. | Ray Sumita | Chief Legal Compliance Officer | S - Sale+OE | $30.09 | -8,829 | 118,545 | -7% | -$265,628 | |||||
| D | 2026-08-13 | CUE | Cue Biopharma, Inc. | Meluzio Michael Vincent | VP, Prin. Accounting Officer | S - Sale+OE | $30.09 | -5,628 | 48,961 | -10% | -$169,324 | |||||
| D | 2026-08-17 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Chief Medical Officer | S - Sale+OE | $111.84 | -7,000 | 32,718 | -18% | -$782,882 | |||||
| D | 2026-08-13 | RYTM | Rhythm Pharmaceuticals, Inc. | Shulman Joseph | Chief Technical Officer | S - Sale+OE | $119.75 | -5,079 | 15,915 | -24% | -$608,210 | |||||
2026-08-13 | RYTM | Rhythm Pharmaceuticals, Inc. | Garfield Alastair | Chief Scientific Officer | S - Sale | $117.57 | -7,763 | 2,295 | -77% | -$912,703 | ||||||
2026-08-13 | RCKT | Rocket Pharmaceuticals, Inc. | Shah Gaurav | CEO | S - Sale | $3.38 | -2,837 | 1,465,125 | 0% | -$9,592 | ||||||
2026-08-13 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $3.38 | -3,493 | 674,484 | -1% | -$11,810 | ||||||
| D | 2026-08-14 | HROW | Harrow, Inc. | Shojaei Amir | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $40.00 | -11,250 | 0 | -100% | -$450,000 | |||||
| M | 2026-08-13 | DYN | Dyne Therapeutics, Inc. | Rhodes Jason P | Dir | S - Sale | $25.20 | -2,586,928 | 431,908 | -86% | -$65,184,894 | |||||
2026-08-13 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $58.68 | -11,002 | 50,390 | -18% | -$645,551 | ||||||
2026-08-17 | KURA | Kura Oncology, Inc. | Wilson Troy Edward | Pres, CEO | P - Purchase | $11.12 | +100,000 | 1,114,650 | +10% | +$1,112,000 | ||||||
| D | 2026-08-14 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $498.91 | -9,500 | 668,728 | -1% | -$4,739,664 | |||||
2026-08-14 | ZVRA | Zevra Therapeutics, Inc. | Thompson Rahsaan | Chief Legal, Compliance | S - Sale | $11.13 | -42,666 | 37,569 | -53% | -$474,774 | ||||||
2026-08-13 | VERU | Veru Inc. | Barnette K Gary | Chief Scientific Officer | P - Purchase | $2.69 | +1,800 | 2,300 | +360% | +$4,842 | ||||||
2026-08-17 | IMNN | Imunon, Inc. | Eylward Susan | GC, Corp Sec | S - Sale | $1.63 | -2,449 | 2,896 | -46% | -$3,993 | ||||||
2026-08-13 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Chief Commercial Officer | S - Sale | $26.28 | -226 | 153,982 | 0% | -$5,939 | ||||||
2026-08-13 | DYN | Dyne Therapeutics, Inc. | Kerr Douglas | Chief Medical Officer | S - Sale | $26.28 | -1,556 | 167,599 | -1% | -$40,892 | ||||||
2026-08-13 | DYN | Dyne Therapeutics, Inc. | Cox John | CEO, Pres | S - Sale | $26.28 | -4,986 | 435,165 | -1% | -$131,032 | ||||||
2026-08-13 | DYN | Dyne Therapeutics, Inc. | Lucera Erick | CFO | S - Sale | $26.28 | -1,797 | 119,766 | -1% | -$47,225 | ||||||
| D | 2026-08-14 | SGMT | Sagimet Biosciences Inc. | Kemble George | Dir | S - Sale+OE | $10.23 | -350,987 | 62,161 | -85% | -$3,591,580 | |||||
| DM | 2026-08-12 | CUE | Cue Biopharma, Inc. | Lin Shao-Lee | CEO | S - Sale+OE | $27.58 | -58,258 | 705,995 | -8% | -$1,606,562 | |||||
| D | 2026-08-12 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | COO | S - Sale+OE | $82.64 | -804 | 54,324 | -1% | -$66,445 | |||||
| D | 2026-08-13 | RYTM | Rhythm Pharmaceuticals, Inc. | Lee Jennifer Kayden | EVP, Head of North America | S - Sale+OE | $117.38 | -75,834 | 0 | -100% | -$8,901,531 | |||||
| D | 2026-08-12 | RYTM | Rhythm Pharmaceuticals, Inc. | Mazabraud Yann | EVP, Head of International | S - Sale+OE | $116.15 | -57,000 | 55,655 | -51% | -$6,620,575 | |||||
2026-08-12 | MANE | Veradermics, Inc | Childs John W | Dir | S - Sale | $107.12 | -100,000 | 2,102,006 | -5% | -$10,711,700 | ||||||
| D | 2026-08-14 | ORKA | Oruka Therapeutics, Inc. | Quinlan Paul T | GC | S - Sale+OE | $108.49 | -52,000 | 31,034 | -63% | -$5,641,409 | |||||
2026-08-12 | SEPN | Septerna, Inc. | Third Rock Ventures V, L.P. | 10% | S - Sale | $50.27 | -147,200 | 10,280,050 | -1% | -$7,399,858 | ||||||
| D | 2026-08-13 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale+OE | $106.66 | -10,000 | 15,312 | -40% | -$1,066,572 | |||||
2026-08-14 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.06 | +1,800 | 9,355,456 | 0% | +$112 | ||||||
2026-08-12 | SEPN | Septerna, Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $42.50 | -1,493,000 | 725,443 | -67% | -$63,452,500 | ||||||
| D | 2026-08-12 | LGND | Ligand Pharmaceuticals Inc | Espinoza Octavio | CFO | S - Sale+OE | $292.07 | -31,641 | 27,696 | -53% | -$9,241,229 | |||||
| D | 2026-08-12 | LGND | Ligand Pharmaceuticals Inc | Haas Jason | Dir | S - Sale+OE | $292.81 | -7,138 | 3,981 | -64% | -$2,090,062 | |||||
| DM | 2026-08-12 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale+OE | $43.71 | -9,441 | 8,625 | -52% | -$412,703 | |||||
| D | 2026-08-12 | EWTX | Edgewise Therapeutics, Inc. | Russell Alan J | Chief Scientific Officer | S - Sale+OE | $43.73 | -5,901 | 31,466 | -16% | -$258,042 | |||||
| D | 2026-08-12 | EWTX | Edgewise Therapeutics, Inc. | Moore John R | GC | S - Sale+OE | $43.82 | -5,016 | 17,697 | -22% | -$219,823 | |||||
| D | 2026-08-12 | EWTX | Edgewise Therapeutics, Inc. | Derakhshan Behrad | Chief Business Officer | S - Sale+OE | $43.81 | -5,100 | 31,826 | -14% | -$223,424 | |||||
| D | 2026-08-12 | EWTX | Edgewise Therapeutics, Inc. | Koch Kevin | Pres, CEO | S - Sale+OE | $43.68 | -17,971 | 52,488 | -26% | -$785,042 | |||||
| D | 2026-08-13 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $504.24 | -9,500 | 668,728 | -1% | -$4,790,316 | |||||
| D | 2026-08-13 | JNJ | Johnson & Johnson | Duato Joaquin | CEO, COB | S - Sale+OE | $261.17 | -123,291 | 307,837 | -29% | -$32,199,927 | |||||
2026-08-13 | AMRX | Amneal Pharmaceuticals, Inc. | Kiely John | Dir | S - Sale | $17.64 | -50,000 | 200,252 | -20% | -$882,000 | ||||||
2026-08-12 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $71.50 | +951 | 509,887 | 0% | +$67,997 | ||||||
2026-08-14 | ABCL | Abcellera Biologics Inc. | Booth Andrew | CFO | P - Purchase | $10.32 | +37,200 | 613,759 | +6% | +$383,904 | ||||||
2026-08-12 | ABCL | Abcellera Biologics Inc. | Hayden Michael R | Dir | P - Purchase | $10.37 | +46,387 | 1,438,029 | +3% | +$481,033 | ||||||
2026-08-12 | BLTE | Belite Bio, Inc | Chuang Hao-Yuan | CFO | S - Sale | $180.35 | -367 | 93,433 | 0% | -$66,187 | ||||||
2026-08-12 | BLTE | Belite Bio, Inc | Lin Yu-Hsin | CEO | S - Sale | $180.35 | -365 | 170,569 | 0% | -$65,827 | ||||||
| D | 2026-08-11 | WVE | Wave Life Sciences, Inc. | Wagner Heidi L | Dir | S - Sale+OE | $6.01 | -7,000 | 44,930 | -13% | -$42,070 | |||||
2026-08-12 | WVE | Wave Life Sciences, Inc. | Rawcliffe Adrian | Dir | S - Sale | $5.29 | -12,700 | 0 | -100% | -$67,183 | ||||||
2026-08-11 | WVE | Wave Life Sciences, Inc. | Takanashi Ken | Dir | S - Sale | $6.01 | -3,864 | 9,626,487 | 0% | -$23,223 | ||||||
2026-08-11 | WVE | Wave Life Sciences, Inc. | Tan Aik Na | Dir | S - Sale | $6.01 | -432 | 24,968 | -2% | -$2,596 | ||||||
| D | 2026-08-11 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $360.00 | -2,666 | 325,312 | -1% | -$959,760 | |||||
| DM | 2026-08-11 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale+OE | $26.33 | -15,000 | 119,289 | -11% | -$394,897 | |||||
| D | 2026-08-11 | SEPN | Septerna, Inc. | Bhatt Elizabeth | Pres, COO | S - Sale+OE | $44.00 | -25,000 | 174,209 | -13% | -$1,100,000 | |||||
2026-08-11 | ABT | Abbott Laboratories | Morrone Louis H. | EVP | S - Sale | $109.83 | -5,850 | 70,724 | -8% | -$642,506 | ||||||
| D | 2026-08-12 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $515.03 | -9,500 | 668,728 | -1% | -$4,892,748 | |||||
2026-08-11 | KRRO | Korro Bio, Inc. | Formela Jean Francois | Dir | S - Sale | $13.96 | -2,143 | 145,937 | -1% | -$29,916 | ||||||
2026-08-13 | MRK | Merck & Co., Inc. | Guindo Chirfi | EVP, Access, Policy, Comms | S - Sale | $135.00 | -10,000 | 36,613 | -21% | -$1,350,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |